問卷

TPIDB > Search Result

Search Result

篩選

List

14Cases

2025-04-01 - 2032-12-31

Not yet recruiting
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02
  • Condition/Disease

    Carcinoma, Non-Small-Cell Lung

  • Test Drug

    Capsules Intravenous infusion Intravenous infusion

Participate Sites
18Sites

Recruiting18Sites

2024-01-01 - 2040-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2018-08-01 - 2026-12-01

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting8Sites

2019-03-01 - 2026-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2020-01-01 - 2026-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2020-06-01 - 2029-05-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2020-05-08 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2019-08-30 - 2024-12-17

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2020-07-01 - 2023-11-01

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2018-11-02 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

1 2